Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216521 · ClinicalTrials.gov registry record
Intent of Surgery for IPMN
A clinical trial of Intraductal Papillary Mucinous Neoplasm, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 14
- Study locations
NCT07216521: Recruiting study of Intraductal Papillary Mucinous Neoplasm, sponsored by NYU Langone Health.
NCT07216521 is a study of Intraductal Papillary Mucinous Neoplasm that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 2,000 participants, above the 1,781-participant average among 4 other Intraductal Papillary Mucinous Neoplasm trials with a reported enrollment target (12% higher). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07216521, a study of Intraductal Papillary Mucinous Neoplasm, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 14
- Study locations
Study Summary
This multicenter retrospective observational cohort study seeks to: 1. Classify surgical intent in patients with resected Intraductal Papillary Mucinous Neoplasms (IPMN) and quantify the proportion of IPMN-associated cancers diagnosed as overt pancreatic cancer with incidental IPMN association on pathology. 2. Compare clinicopathologic features and outcomes between surveillance-detected and incidentally detected IPMN-derived pancreatic cancers. 3. Revise and redefine risk features limited to patients undergoing surgery for IPMN-related indications, identifying optimal predictors of malignant IPMN (high-grade dysplasia or invasive cancer).
Conditions Studied
Study Locations (14)
Other
- Nanjing University - Nanjing
- Heidelberg University - Heidelberg
- San Raffaele Hospital - Milan
- Padua University - Padua
- University of Amsterdam - Amsterdam
- University of Utrecht - Utrecht
New York
- NYU Langone Health - New York
- Memorial Sloan Kettering - New York
Arizona
- Mayo Clinic - Phoenix
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Duke University - Durham
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2025-12 |
What NCT07216521 shows while recruiting
NCT07216521 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,781-participant average among 4 other Intraductal Papillary Mucinous Neoplasm trials with a reported enrollment target (12% higher).
The record links to 1 condition, with Intraductal Papillary Mucinous Neoplasm appearing as the primary indexed condition, and to 0 interventions.
NCT07216521 lists 14 locations in 8 states (Other, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT07216521 about?
NCT07216521 is a clinical study titled "Intent of Surgery for IPMN". This multicenter retrospective observational cohort study seeks to: 1. Classify surgical intent in patients with resected Intraductal Papillary Mucinous Neoplasms (IPMN) and quantify the proportion of IPMN-associated cancers diagnosed as overt pancreatic cancer with incidental IPMN association on p...
What is the current status of trial NCT07216521?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2025-09-15. Estimated completion is 2025-12.
What conditions does trial NCT07216521 study?
This clinical trial studies the following conditions: Intraductal Papillary Mucinous Neoplasm.
Who is sponsoring clinical trial NCT07216521?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216521 being conducted?
This trial has 14 study locations across Arizona, Maryland, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intraductal Papillary Mucinous Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI